Tianjin Cancer Hospital
Tianjin Cancer Hospital
Tianjin, China10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 3 | 2026-09-16 | NCT07823049 | |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | Active, not recruiting | Phase 3 | 2026-09-14 | NCT06065748 | |
| A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | HER2-positive Breast Cancer | Active, not recruiting | Phase 3 | 2026-07-23 | NCT03975647 | |
| A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-05-05 | NCT06214143 | |
| IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer | Platinum-resistant Ovarian Cancer | Recruiting | Phase 1 / Phase 2 | 2026-05-04 | NCT05551507 | |
| A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors | Advanced Solid Cancer | Recruiting | Phase 1 | 2025-12-05 | NCT07265921 | |
| JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2025-09-12 | NCT06079983 | |
| Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Lymphoma, High-Grade, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Tumor Virus Infections, diffuse large B-cell lymphoma, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Active, not recruiting | Phase 2 | 2025-01-14 | NCT05263583 | |
| A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Recruiting | Phase 3 | 2024-12-27 | NCT06363994 | |
| ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas | Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Recruiting | Phase 2 | 2024-08-23 | NCT05830123 |